Raptinal manufacturers
- Raptinal
-
- $1.10
-
2026-08-25
- CAS:1176-09-6
- Min. Order: 1kg
- Purity: 99%
- Supply Ability: 50kg
- Raptinal
-
- $115.00
-
2026-07-27
- CAS:1176-09-6
- Purity: 97.62%
- Supply Ability: 10g
|
| | Raptinal Basic information |
| Product Name: | Raptinal | | Synonyms: | Raptinal;[9,9'-Bi-9H-fluorene]-9,9'-dicarboxaldehyde;9H,9'H-[9,9'-Bifluorene]-9,9'-dicarbaldehyde;Raptinal, 10 mM in DMSO;9H,9'H-[9,9'-Bifluorene]-9,9'-dicarbaldehyde | | CAS: | 1176-09-6 | | MF: | C28H18O2 | | MW: | 386.44 | | EINECS: | | | Product Categories: | | | Mol File: | 1176-09-6.mol |  |
| | Raptinal Chemical Properties |
| Melting point | 219 °C | | Boiling point | 531.3±50.0 °C(Predicted) | | density | 1.378±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO : 33.33 mg/mL (86.25 mM; Need ultrasonic) | | form | powder to crystal | | color | White to Almost white | | InChI | 1S/C28H18O2/c29-17-27(23-13-5-1-9-19(23)20-10-2-6-14-24(20)27)28(18-30)25-15-7-3-11-21(25)22-12-4-8-16-26(22)28/h1-18H | | InChIKey | GLANOOJJBKXTMI-UHFFFAOYSA-N | | SMILES | O=CC(C1=C2C=CC=C1)(C3(C=O)C4=C(C5=C3C=CC=C5)C=CC=C4)C6=C2C=CC=C6 |
| WGK Germany | WGK 2 | | HS Code | 2912.29.6090 | | Storage Class | 11 - Combustible Solids | | Hazard Classifications | Eye Irrit. 2
Skin Irrit. 2
STOT SE 3 |
| | Raptinal Usage And Synthesis |
| Uses | Raptinal showed complete cytochrome c release within 30 minutes and caspase-3 activation within one hour of exposure (10 μM). Despite its general cytotoxicity in both cancer and non-cancer cell cultures (Cell death induction EC50 = 0.6-3.4 μM in 24 hr), no hematologic toxicity was observed 7 days following single 60 mg/kg i.v. dosing in mice. Studies show th at daily i.p. injection (20 mg/kg) is efficacious in suppressing murine B16-F10 melanoma and 4T1 breast cancer expansion in vivo (by ~60% and 50% in 6 days, respectively). | | Biological Activity | Raptinal is a cell-permeable bifluorene-dicarbaldehyde compound th at acts as a rapid activator of mitochondrial pathway-mediated intrinsic apoptosis. | | in vivo | Raptinal is an unusually rapid inducer of caspase-dependent apoptosis in multiple cell lines and in vivo systems[1].
Raptinal (20 mg/kg; administered intraperitoneally; once daily for 3 consecutive days for B16-F10 and 4 consecutive days for 4T1 models) exerts anticancer activity in vivo[2].
C57BL/6 mice are administered intravenous Raptinal across a range of dosages as a one-time injection. When administered intravenously at a dosage of 37.5 mg/kg, the peak plasma concentration and elimination half-life of Raptinal are 54.4±0.9 μg/mL and 92.1±5.8 minutes, respectively. Single-dose intravenous Raptinal is well tolerated across a wide dose range (15-60 mg/kg) and does not cause hematologic toxicity as assessed 7 days post-administration[2]. | Animal Model: | C57BL/6 and BALB/c female mice (6-8 weeks old) bearing the B16-F10 model or 4T1 models[2] | | Dosage: | 20 mg/kg | | Administration: | Administered intraperitoneally; once daily for 3 consecutive days for B16-F10 and 4 consecutive days for 4T1 models | | Result: | Retard tumor volume and tumor mass by 60% relative to controls in the B16-F10 model.
Similar efficacy was observed for the 4T1 murine breast cancer tumor model with 50% growth inhibition after treatment.
|
| | IC 50 | Caspase 3 |
| | Raptinal Preparation Products And Raw materials |
|